Fig. 1From: Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart reviewStudy population and treatment cohorts. Anti-TNFα: anti-tumor necrosis factor alpha; CD: Crohn’s disease; UC: ulcerative colitis; VDZ: vedolizumabBack to article page
